Floatz logo

Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes

Cytomegalovirus Infection

M.D. Anderson Cancer CenterCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Cytomegalovirus Infection cohort.

Asset / SponsorPhaseRating
Foscarnet
City of Hope Medical Center
Phase 4BB
Valganciclovir
The Methodist Hospital Research Institute
Phase 3BB
Ganciclovir
City of Hope Medical Center
Phase 3BB
Cmvpp65-A*0201 Peptide Vaccine
City of Hope Medical Center
Phase 2B
Letermovir
Fernanda P Silveira, MD, MS
Phase 2B

View all 13 →

Same molecule, other indications

Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes is also rated in:

hematopoietic and lymphoid cell neoplasmActive
CCC
Indicative · Phase 2
53 / 100
View asset →
cancerActive
CCC
Indicative · Phase 2
53 / 100
View asset →
large-cell immunoblastic lymphomaDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →